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A B S T R A C T
Purpose: To compare the long-term retention rates of the two most commonly prescribed antiepileptic
drugs (AEDs), carbamazepine (CBZ) and valproate (VPA) as an initial monotherapy in Chinese patients
with partial seizures.
Methods: This is a retrospective, observational study in a tertiary epilepsy centre. Overall, 584 patients
were followed during a ten-year period. Kaplan–Meier survival analysis was used to estimate the
cumulative probability of retention. Cox proportional hazard model was used to analyze the risk factors
for retention rate.
Results: The calculated retention rates estimated by Kaplan–Meier survival analysis showed no
difference between CBZ and VPA (p = 0.074). During the time period from the ﬁrst six months to two
years, the lack of efﬁcacy (LE) that led to drug discontinuation was 10.7% for CBZ compared to 4.5% for
VPA (p = 0.004). The adverse effects (AEs) that led to discontinuation was 2.4% for CBZ compared to 6.3%
for VPA (p = 0.025). Clinical control that led to discontinuation was 15.9% for CBZ compared to 7.5% for
VPA (p = 0.001). The ﬁve-year remission rate was higher in the CBZ group (33.3%) than in the VPA group
(23.2%, p = 0.006). Yet in the complex partial seizure subgroup, there was no signiﬁcant difference
between the two drugs (p = 0.61).
Conclusion: Compared with VPA, patients treated with CBZ were more likely to discontinue treatment
for LE, and were less likely to discontinue for AEs; however, the two differences above only occurred in
the time period between the ﬁrst six months to two years of treatment. Long-term treatment with CBZ
appeared to be more effective in terms of ﬁve-year remission and clinical control than VPA.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of themost commonneurological diseases and it
affects approximately nine million people in China with an annual
number of 0.4–0.6 million newly diagnosed epileptic patients.1
Antiepileptic drugs (AEDs) are generally prescribed to control
seizures in this patient population. Although more than ten newer
antiepileptic drugs have been licensed for treating epilepsy in the
past two decades,2,3 carbamazepine (CBZ) and valproate (VPA) are
still considered to be the ﬁrst-line treatments for patients with
partial seizures, and these medications are commonly prescribed
in China. This trend has occurred due to the ﬁnancial burden the
newly drugs place on patients’s families. Additionally, some
comparative trials of the newly drugs compared to CBZ or VPA* Corresponding author. Tel.: +86 23 89012878; fax: +86 23 68811487.
E-mail address: kudosai@163.com (X.-F. Wang).
1 The authors contributed to this study equally.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.11.020indicated that the newer agents have demonstrated a similar
efﬁcacy and tolerability to the two standard AEDs.4–9 CBZ is a drug
of choice for partial seizures (simple, complex and secondarily
generalized tonic–clonic seizures)10 and VPA is a broad-spectrum
AED with a good response for both partial and generalized
onsets.7,11 The efﬁcacy and tolerability of these two drugs have
been investigated,12–14 yet a large sample, long-term follow-up,
comparison between CBZ and VPA as an initial monotherapy in
patients with newly diagnosed partial seizures has not been
performed for Chinese population. One way to assess the long-
term performance of AEDs in daily clinical practice is to evaluate
the retention rates. Compared with the other outcomes for
estimating AEDs, such as the reduction of seizures, or the time
to ﬁrst seizure onset, the retention rate is more composite,15,16 and
was recommended by the International League Against Epilepsy
(ILAE).17 In many previous studies that evaluated retention rates,
the follow-up periods were rarely more than 6 years, however, for
measuring important clinical outcomes of long-term seizure
control,18 a long follow-up period is necessary. Therefore, wevier Ltd. All rights reserved.
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and VPA over a ten year follow-up period to provide more useful
information for the clinical practice. To our knowledge this is the
ﬁrst study that compares the long-term retention rates between
CBZ and VPA as an initial monotherapy in Chinese patients.
2. Methods
2.1. Patients and procedures
This study was approved by the Medical Ethics Committee at
Chongqing Medical University. A total of 584 patients with newly
diagnosed partial seizures, who were initially prescribed with CBZ
or VPA during a period from September 1996 to January 2000,were
identiﬁed through an electronic record search. The inclusion
criteria included the following: (1) patients who were deﬁnitively
diagnosed with partial seizures who never received AED(s). The
seizure types and the types of epilepsy were deﬁned according to
the International League Against Epilepsy (ILAE)19; (2) patients
without contraindications for CBZ or VPA treatment; (3) patients
who had at least one seizure onset within half a year before
therapy. The exclusion criteria included the following: (1) patients
with progressive central neurological diseases; (2) patients with
clinically signiﬁcant organic diseases before treatment, such as
abnormal liver function, abnormal kidney function, abnormal
haematological system function, abnormal endocrine system
function, or heart diseases; (3) patients with acute symptomatic
seizures; (4) patients with a history of psychiatric problems; (5)
patients who were deﬁnitively diagnosed with epilepsy syn-
dromes. The deﬁnition of an epilepsy syndrome was according to
the ILAE.20
The baseline demographic and follow-up data, biomedical
testing records, electroencephalogram (EEG) and neuroimaging
information including computer tomography (CT) and magnetic
resonance imaging (MRI) for each patient were collected in case
record forms in detail. The patients registration information
contained gender, weight, age of ﬁrst seizure onset, course of
epilepsy, frequency of seizure before treatment, history of learning
disabilities or developmental delay, history of febrile seizure,
history of epilepsy in a ﬁrst degree family members, and the
underlying aetiology of the seizures. Blood routine, urine routine,
liver function, kidney function and electrocardiogram (ECG) were
examined. EEG and neuroimaging were also performed during the
ﬁrst visit. Clinicians were asked to classify the types of seizure
onsets (simple partial onset, complex partial onset, or secondary
generalized onset) according to ILAE guidelines, as quickly as
possible. During the follow-up period, medical diaries were
recorded in detail, which included the type of seizures, the
occurrence of seizures, simultaneous phenomena, adverse events,
and hospital admissions. For adverse events, clinicians were asked
to identify whether the events were clinically signiﬁcant. The
patients were required to return for a follow-up visit at the second
week, the ﬁrst month, the third month, the sixth month, and
successive half-year intervals from the date of initial treatment.
The diaries were brought to the clinicians at each visit. If clinically
necessary, more visits were completed. Blood routine test, serum
drug concentration test, liver and kidney function tests, ECG and
EEG recording were performed based on the requirement of
clinical practice. If the patients did not visit the clinicians regularly,
follow-up was obtained through a telephone interview with a
speciﬁc clinician. If the contact with the patient was lost for more
than one year, the patient was deﬁned as a follow-up loss.
The drug dosage and titration were used by the clinicians in
their daily practices. In general, the starting dosage of CBZ for
children was ﬁve milligrams per kilogram per day (5 mg/kg d),
with a weekly escalation of 5 mg/kg d until the target dosage (10–20 mg/kg d) was reached. The initial dosage for adolescents was
200 mg/d, with a weekly escalation of 100 mg/d until the target
dosage (300–600 mg/d) was reached. The initial dosage for adults
was 200–300 mg/d, with one day escalation of 100 mg/d until the
target dosage (300–600 mg/d) was reached. The maximum dosage
for adults was 1200 mg/d. The starting dosage of VPA for children
was 15 mg/kg d, with a weekly escalation of 5–10 mg/kg d. The
maximum dosage for children could be up to 30 mg/kg d, if
necessary. The starting dosage of VPA for adolescents and adults
was 400 mg/d, with a weekly escalation of 100–200 mg/d until the
target dosage (600–1800 mg/d) was reached. The maximum
dosagewas 2000 mg/d for adolescents and adults. Themedications
could be adjusted at the clinicians’ discretions. The strategy of
titration was performed as follows: an AED was given with an
initial small dosage and the dosagewas slowly escalated over time;
the dosage was increased or decreased depending on the balance
between efﬁcacy and adverse events.
2.2. Evaluations and assessments
The end point of this study was the time to treatment
discontinuance. The reasons for discontinuance included: adverse
effects (AEs), lack of efﬁcacy (LE), follow-up loss, poor compliance,
and clinical controls. A patient who had poor compliance with a
clinician’s prescription was deﬁned as a patient who discontinued
CBZ or VPA by their own volition. A patient who was seizure free
for ﬁve consecutive year with a normal neurologic examination,
intelligence quotient (IQ) and EEG results, were considered for
discontinuation of AEDs by a clinician.21 When CBZ or VPA was to
be discontinued by clinician’s recommendation, the drug was
eliminated from the patient’s regimen, by tapering the dose slowly
over 6 months. During this time period, if recurrence of seizures
was observed, the prior dosage was reinstituted at the previously
effective level; if no recurrence, the patient was considered to be
clinically controlled.
Efﬁcacy was evaluated by seizure freedom rates and ﬁve-year
remission rates. Seizure freedom was deﬁned as no seizure onset
for at least twelve months at end of each year. A ﬁve-year
remission was deﬁned as no seizure onset for at least ﬁve
consecutive years. The twelve-month seizure frequency before
AED treatment was considered to be the baseline. If the course of
epilepsy was less than twelve months, the frequency of baseline
was assessed using the formula below:
Frequency ðtimes=yearÞ ¼ times of seizures
course of epilepsy ðdaysÞ  365 ðdaysÞ:
2.3. Statistical analysis
Cox proportional hazard model (95% conﬁdence interval) was
established to analyze the risk factors of AED discontinuations
(which included factors such as: gender, age of ﬁrst seizure onset,
seizure duration before treatment, frequency of baseline, type of
seizure, and choice of AED). Intention-to-treat (ITT) analysis was
used to analyze the seizure freedom rates, the ﬁve-year remission
rates, and the retention rates. Kaplan–Meier survival analysis was
used to estimate the cumulative probability of retention; log-rank
test was used to analyze the comparison between the retention
curve of CBZ and VPA. The differences in the Kaplan–Meier curves
between the two groups were estimated by 95% conﬁdence
intervals. The reasons for censoring in Kaplan–Meier analysis were
deﬁned as follows: during the medication period, patients suffered
tumours, but the tumours were not caused by AED treatment;
patients who died, but the death had no association with AED
Table 1
The basic information and clinical characteristics of patients.
Characteristic Carbamazepine Valproate
Number of patients 252 332
Gender (n, %)
Male 135 (53.6%) 197 (59.3%)
Female 117 (46.4%) 135 (40.7%)
Age of ﬁrst seizure onset (years) 20.911.8 22.414.6
Children and adolescents (n, %) 129 (51.2%) 167 (50.3%)
Adults and elders (n, %) 123 (48.8%) 165 (49.7%)
Age of ﬁrst visit (years) 22.612.2 24.314.7
Children and adolescents (n, %) 120 (47.6%) 150 (45.2%)
Adults and elders (n, %) 132 (52.4%) 180 (54.8%)
Seizure duration before treatment (years) 1.63.7 1.83.6
Type of seizure (n, %)
Simple 13 (5.2%) 18 (5.5%)
Complex 14 (5.6%) 30 (9.0%)
Secondary generalized 225 (89.2%) 284 (85.5%)
Frequency of baseline (n, %)
20 per year 175 (69.4%) 218 (65.7%)
>20 per year 77 (30.6%) 114 (34.3%)
Children and adolescents: age<18 year-old and Adults and elders18 year-old.
[()TD$FIG]
Fig. 1. The retention rate of carbamazepine versus valproate. The cumulative
probabilities of retention for carbamazepine and valproate were estimated by
Kaplan–Meier analysis.
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operations had no association with antiepileptic treatment;
patients who had the plans of pregnancy; patients who still
continued AED treatment at the end of this study. Chi-square test
and Fisher’s probabilistic method were used to analyze the data
between both drugs in terms of seizure remission and reason for
discontinuation. A t-test was performed for independent two-
sample data. The data were expressed as mean  standard
deviation (SD). All of the statistical analyses were performed with
SPSS v17.0 software for windows.
3. Results
3.1. Basic information
A total of 584 patients were enrolled in our study: 252 received
CBZ and 332 received VPA. Table 1 lists the basic information of the
patients. The mean age was 22.6  12.2 years for CBZ and
24.3  14.7 years for VPA. The age of ﬁrst seizure onset was
20.9  11.8 years for CBZ and 22.4  14.6 years for VPA. The mean
duration before treatment was 1.6  3.7 years and 1.8  3.6 years
respectively. The two groups were balanced for clinical and
demographic factors.
3.2. Retention rate
One year after the treatment began, for CBZ: 196 patients
(77.8%) continued, with the annual discontinuation rate of 8.6%
(range 3.6–22.2%); for VPA: 253 (76.2%) patients continued, withTable 2
Actual retention rates at speciﬁc time periods between carbamazepine and
valproate.
Carbamazepine Valproate p value
1 Year 77.8% 76.2% 0.655
2 Years 65.9% 69.0% 0.475
3 Years 59.5% 66.6% 0.321
4 Years 50.4% 50.3% 0.988
5 Years 44.3% 48.2% 0.201
6 Years 38.1% 44.9% 0.161
7 Years 33.3% 35.1% 0.722
8 Years 24.7% 26.3% 0.764
9 Years 21.1% 15.2% 0.259
10 Years 13.6% 7.7% 0.192the annual discontinuation rate of 9.2% (range 2.1–23.8%). The
calculated retention rate estimated by Kaplan–Meier survival
analysis showed a similar result. There was no signiﬁcant
difference in the actual retention rate between the CBZ and VPA
groups, which were investigated at speciﬁc time-periods (Table 2).
Log rank testing for the survival curves in Fig. 1, also showed no
signiﬁcant difference between the two AEDs (p = 0.074). A Cox
proportional hazard model revealed that gender (p = 0.181), age of
ﬁrst seizure onset (p = 0.759), seizure duration before treatment
(p = 0.128), frequency of baseline (p = 0.867), type of seizure
(complex: simple, p = 0.207; secondary generalized: simple,
p = 0.415), and choice of AED (p = 0.09) were not risk factors for
treatment discontinuations in our study.
The causes for CBZ and VPA discontinuation are shown in Table
3. Clinical control that led to drug discontinuation represented
15.9% of CBZ treated patients compared to 7.5% of VPA patients
(p = 0.001). During the time period from the ﬁrst six months to two
years after the initial treatment, LE leading to drug discontinuation
occurred for 10.7% of CBZ patients compared to 4.5% of VPA
patients (p = 0.004), AEs that led to drug discontinuation repre-
sented 2.4% of CBZ patients compared to 6.3% of VPA patients
(p = 0.025). For CBZ, during the ﬁrst ﬁfteen days of treatment,
follow-up loss was the most important cause for drug discontinu-
ation. Afterwards, AEs were the major cause between ﬁfteen days
to six months after initial treatment. Then LE was the most
frequent reason from six months to two years. After six years,
clinical control became the major cause for medication discontin-
uation. For VPA, during the ﬁrst month, follow-up loss was the
most important cause for drug discontinuation. Afterwards LE and
poor compliance were the two most important causes during the
one- to three-month period after initial treatment. Then AEs were
themost frequent reason for discontinuation from threemonths to
six months. From six months to one year, LE was the most cited
reason again. From one to two years, AEs and follow-up loss wereTable 3
Comparison of discontinuation causes between carbamazepine and valproate.
Carbamazepine Valproate p value
Lack of efﬁcacy 41 (16.3%) 35 (10.5%) 0.047
Adverse effects 28 (11.1%) 34 (10.2%) 0.735
Follow-up loss 47 (18.7%) 60 (18.1%) 0.858
Poor compliance 33 (13.1%) 29 (8.7%) 0.090
Clinical control 40 (15.9%) 25 (7.5%) 0.001
Table 4
Seizure freedom rates during the follow-up period for carbamazepine and
valproate.
Carbamazepine Valproate p value
T0–1 Year 52.4% 51.8% 0.891
T1–2 Years 55.2% 51.8% 0.421
T2–3 Years 49.6% 39.2% 0.015
T3–4 Years 41.9% 36.5% 0.221
T4–5 Years 41.3% 32.2% 0.051
T5–6 Years 40.0% 25.6% 0.021
T6–7 Years 31.4% 22.7% 0.098
T7–8 Years 33.6% 22.9% 0.075
T8–9 Years 25.0% 17.9% 0.232
T9–10 Years 21.5% 11.4% 0.080
Table 6
Adverse effects leading to drug discontinuation at speciﬁc time periods.
Carbamazepine Valproate
2 Weeks Skin rash (1.6%) Abnormalities in liver
function (0.3%)Dizziness (0.8%)
Cardiopalmus (0.4%) Skin rash (0.3%)
Nausea (0.4%)
1 Month Skin rash (1.2%) Lethargy (0.6%)
Dizziness (0.4%)
Cardiopalmus (0.4%) Menstrual disorder (0.3%)
Abnormalities in liver
function (0.4%)
Granulopenia (0.3%)
3 Months Abnormalities in liver
function (1.2%)
Abnormalities in liver
function (0.3%)
Dizziness (0.3%)
Skin rash (0.4%) Fatigue (0.3%)
Pancytopenia (0.3%)
6 Months Abnormalities in liver
function (0.4%)
Weight gain (0.6%)
Memory impairment (0.3%)
Skin rash (0.4%) Lethargy (0.3%)
Granulopenia (0.3%)
Memory
impairment (0.3%)
Word ﬁnding difﬁculty (0.3%)
Alopecia (0.3%)
Alopecia (0.3%) Headache (0.3%)
Tremor (0.3%)
1 Year Memory
impairment (0.4%)
Dizziness (0.6%)
Weight gain (0.3%)
Abnormalities in liver
function (0.3%)
Tremor (0.3%)
Lethargy (0.3%)
Memory impairment (0.3%)
2 Years Cardiopalmus (0.4%) Abnormalities in liver
function (0.9%)
Weight gain (0.3%)
Skin rash (0.3%)
3 Years Abnormalities in liver
function (0.4%)
Abnormalities in renal
function (0.4%)
Hypothyrea (0.3%)
4 Years Dizziness (0.3%)
Menstrual disorder (0.3%)
6 Years Hypothyrea (0.3%) Tremor (0.3%)
Thrombocytopenia (0.3%)
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clinical control was the major cause for medication discontinua-
tion as well as CBZ.
3.3. Efﬁcacy
Table 4 shows the patients who were completely seizure free
for at least one year between each assessment point. Seizure
freedom rates for the intervals T2–3 years and T5–6 years were
signiﬁcantly higher in the CBZ group (p = 0.015 and 0.021,
respectively). For other intervals, no signiﬁcant difference was
founded between the CBZ group and the VPA group; (the p values
ranged from 0.051 to 0.891).
The ﬁve-year remission rate was higher in the CBZ group
(33.3%) than that in the VPA group (23.2%) (p value was 0.006
(Table 5)). In the simple partial seizure subgroup and the
secondary generalized seizure subgroup, the patients treated with
CBZ were more likely to achieve ﬁve-year remission than the
patients treatedwith VPA (61.5%:16.7%, p = 0.021 and 32.0%:23.9%,
p = 0.043, respectively). In the complex partial seizure subgroup,
there was no signiﬁcant difference between the two drugs
(28.6%:16.7%, p = 0.61).
3.4. Adverse effects
Table 6 shows all AEs leading to drug discontinuation between
each assessment point. The four most common AEs for CBZ were
skin rash (in 3.6% patients), abnormalities in liver function (2.4%),
dizziness (1.2%), and cardiopalmus (1.2%). For VPA, abnormalities
in liver function (1.8%), lethargy (1.2%), dizziness (1.2%), and
weight gain (1.2%) were the four most common AEs. In the CBZ
group, more than 70% of AEs that led to discontinuation appeared
within six months after initial treatment, compared to a period of
three months to two years in the VPA group.
4. Discussion
China has the largest population in the world and the most
epileptic patients as well.1 For economic reasons, CBZ and VPA are
far more commonly prescribed for Chinese patients with partialTable 5
Comparison of ﬁve-year remission for carbamazepine and valproate.
Carbamazepine Valproate p value
Total 84 (33.3%) 77 (23.2%) 0.006
Simple 8 (61.5%) 3 (16.7%) 0.021a
Complex 4 (28.6%) 5 (16.7%) 0.610b
Secondary generalized 72 (32.0%) 68 (23.9%) 0.043
a Analyzed by Fisher’s Exact Test.
b Analyzed by continuity correction Chi-square test.seizures than the newer licensed agents in present China. Data on
the efﬁcacy and tolerability of these two AEDs in previous
studies7,22–24 were almost based on Euramerican and Japanese
populations. To account for the differences in genetic, environ-
mental factors, and pharmacokinetic processes among different
populations, the previous reports may be not entirely suitable for
Chinese patients.25 So adding the results from Chinese clinical
trials will be important to antiepileptic practices of the world.
Epilepsy is a chronic neurological disorder, and treatment
requires a long period of time. To assess the long-term perform-
ance of AEDs comprehensively, a substantial period of time for
follow-up is required and a composite indicator must be used.
Long-term retention rate meets these two requirements.15–17 In
our study, there were 584 patients who were observed during a
follow-up period of up to 10 years. To our knowledge, this is the
longest follow-up period from a study conducted in China. The
large number of patients included in this study, the long-term
follow-up period increased the possibility of ﬁnding clinically
important differences between CBZ and VPA. Meanwhile, to
achieve the goal of contributing to everyday clinical practice,
the entry criteria of this study were as inclusive as possible and
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clinical practice.
Retention time on an AED was deﬁned as the time from initial
monotherapy to withdrawal of AED treatment or addition of
another agent. Retention time is customarily considered to be a
composite indicator for evaluating drug efﬁcacy and tolerability.
However some non-drug-related events such as follow-up loss and
poor compliance may also lead to treatment failure.26 These
possibilities were considered to be discontinuation causes in our
Kaplan–Meier survival analysis. The discontinuation of AED
treatment is considered to be a valuable option in the patients
who had been seizure free for ﬁve years or longer.21 Based on these
ﬁndings, the decisions of terminating AED treatment were made
for the patients who were well controlled for at least ﬁve
consecutive years and had normal neurologic examinations,
intelligence quotient (IQ) and EEG results as well as no recurrence
of seizures during the decrement period. Once the patients had
successfully terminated CBZ or VPA, they would be considered to
be clinically controlled. Some patients relapsed after the medica-
tion was withdrawn, and the subsequent research focus on the
factors associated with risk of seizure relapse in Chinese epileptic
patients was performed in our centre with speciﬁc methodological
design, but the results have not been included in this article.
Previously, for time to treatment discontinuation, a meta-
analysis of randomized controlled trials showed that therewas ‘‘no
reliable evidence to distinguish CBZ and VPA for partial-onset
seizures’’.7 This ﬁnding was similar to ours. Yet in these studies the
retention rates of CBZ and VPA that were reported that at the one-
year time point were around 60–70%, and decreased to around 20–
30% after four years of follow-up.7,27 The differences between the
current study and previous reports may be due to: (1) the Chinese
population selected in our study had better response for CBZ and
VPA than other populations recruited in the early investigations;
(2) the patients were only newly diagnosed in our study, but in
previous there were more patients that may have turned out to be
refractory before the investigations started. Interestingly, in
present study, the patients treated with CBZ were more likely to
discontinue medication for LE, but were less likely to discontinue
treatment for AEs than those treatedwith VPA. This difference only
occurred in the time period between the ﬁrst six months to two
years after the initial treatment. This ﬁnding is an important since
it showed that clinicians should pay more attention to efﬁcacy for
patients treated with CBZ, and more attention to tolerability for
patients treated with VPA during this time period.
The main objective of epilepsy treatment is to control seizures,
since seizure onset has the greatest impact on quality of life.28 Thus
we chose to examine seizure freedom rates and ﬁve-year remission
rates to measure efﬁcacy. It is notable that the seizure freedom
rates of both CBZ and VPA did not decrease gradually but decreased
apparently every two to three years followed by a relatively stable
phase. Comparable percentages of patients achieved seizure
freedom with both drugs before two years. After this period of
time, more patients on CBZ achieved seizure freedom for at least
one additional year (although not all of these differences were
statistically signiﬁcant). Based on our results the seizure freedom
rates of VPA decreased faster than those of CBZ, and there is a two-
to three-year stable-decreased-stable cycle for seizure freedom
rates for both drugs. Generally, the effective rate of drug treatment
decreases over time. However, the stable-decreased-stable cycle
was observed for the ﬁrst time in Chinese epileptic patients, and
our results could contribute to clinicians’ daily practices. The
percentage of patients who achieved ﬁve-year remission was
higher in CBZ-treated group than in VPA-treated group. This
difference occurred due to the fact that CBZ had a better seizure
freedom outcome than VPA. In previous randomized controlled
trials comparing CBZ and VPA, evidence was provided that CBZ-treated patients was better on the outcomes of time to ﬁrst seizure
and time to twelve-month remission.10,23,24 Our ﬁndings showed
that CBZwas also better than VPA for the long-term seizure control
in Chinese patients with simple partial onset and secondary
generalized onset.
In this study, 25.9% of patients treated with CBZ and 33.3% of
patients treated with VPA reported adverse events. 11.1% and
10.2% of the CBZ and VPA patients discontinued medication due to
AEs, respectively. No death or life-threatening AEs appeared during
follow-up. The percentage of patients who discontinued treatment
due to AEs for either drug was comparable, and discontinuations
occurred quite early in the course of medication, usually within
one year of initial treatment. Our ﬁndings showed that if the
medication is initially well tolerated, the long-term tolerability of
CBZ and VPA for Chinese epileptic patients is good. Rash was
commonly considered to be a serious AE in previous studies, and
the discontinuations due to rashes largely occurred within the ﬁrst
two to eight weeks after drug initialization.29 In our study, skin
rash complaints were the most common adverse event for
discontinuation in the CBZ group. In contrast to only a few
patients discontinued treatment for skin rash in the VPA group.
Abnormalities in liver function were reported for both AEDs, liver
problems were the most common cause for discontinuation in the
VPA group, although the percentage of patients with abnormalities
in liver function was higher in the CBZ group.
Follow-up losswas themost common cause of discontinuation
of treatment in our study. Although clinicians informed the
patients that epilepsy is a chronic disease and requires long-term
treatment, approximately 50% of follow-up loss events occurred
within the ﬁrst two weeks after initial treatment. Compared with
the non-loss cohort, the percentage of patients living far from our
centre in the follow-up loss cohort was much higher. Long
distance travel incurs a higher cost of time and traveling expenses
for each visit, and this higher cost likely aggravated the economic
and mental burden of the patients, especially since some of those
patients have told the clinicians that they were afraid of being
ﬁred for frequent absences at work. Limited forms of communi-
cation may be the other cause for patient follow-up loss. We only
recorded the patient’s telephone number and address, since these
two kinds of communication are the most common ways to
communicate with patients in China. For decreasing follow-up
loss in the future, collecting more contact information could be
useful.
5. Conclusion
Our study suggested that there is no signiﬁcant difference in
retention rates between CBZ and VPA as an initial monotherapy for
Chinese patients with partial seizures. Lack of efﬁcacy, adverse
effects, follow-up loss, poor compliance and clinical control were
the causes leading to discontinuations of treatment. Patients
taking CBZ were more likely to discontinue treatment because of
clinical control. Additionally, between the ﬁrst six months to two
years, the patients treated with CBZ were more likely to
discontinue treatment for LE, but they were less likely to
discontinue treatment for AEs than patients treated with VPA.
The patients with simple partial seizure onset and secondary
generalized onset treated with CBZ were more likely to achieve
long-term remission than those treated with VPA. The most
common intolerable AE for CBZ was rash and themost common AE
for VPA was abnormalities in liver function.
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